Login to Your Account

MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M

By Nuala Moran
BioWorld Today Correspondent

Thursday, December 1, 2011
In a potential $450 million deal, MacroGenics Inc., has signed up the privately held French pharmaceutical company Servier as partner for MGA271, a first-in-class antibody targeting B7-H3, an antigen that is expressed in a long and growing list of solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription